The original Novartis product carries the same indication as well as an indication for adult and pediatric patients aged ≥ 2 years with tuberous sclerosis complex–associated partial-onset ...

and seizures in tuberous sclerosis complex (TSC), along with PDE10a inhibitor gemlapodect (NOE-105) in a phase 2b study in Tourette's syndrome, and NOE-115, a broad-spectrum monoamine modulator in ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. On a fourth-quarter earnings call with the media this morning ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. Now, the rising class of bispecifics opened up an opportunity for the Swiss pharma to reenter the space ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of ...

Proposed Dividend: CHF 3.50 per share, a 6% increase. Novartis AG (NYSE:NVS) reported a strong financial performance for 2024, with a 16% increase in Q4 sales and a 29% rise in core operating ...

Novartis NOVN1.54%increase; green up pointing triangle forecasts further profit and sales growth this year after beating analysts’ expectations in the fourth quarter of 2024, despite looming ...

With its Q4 2024 financials on Friday, Novartis (NYSE:NVS) (OTCPK:NVSEF) indicated a delayed timeline for initial data from a Phase 3 trial for a cardiac therapy it co-develops with Ionis ...

Novartis (NVS) CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if its main focus remains on therapeutic areas where it ...

Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, its chief executive ...